Rallybio Corp Cash Flow Conversion Efficiency
Rallybio Corp cash flow conversion efficiency. Based on the latest financial reports, Rallybio Corp (RLYB) has a cash flow conversion efficiency ratio of 0.482x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($45.55 Million) by net assets ($94.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Rallybio Corp (2019–2025)
Cash flow conversion efficiency of Rallybio Corp from 2019 to 2025. This chart illustrates how Rallybio Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Rallybio Corp share price for real-time trading data and today's change.
Rallybio Corp Cash Flow Conversion Ratio Explained
Rallybio Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Rallybio Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rallybio Corp ranked by their cash flow conversion efficiency. Also see RLYB stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Goltas Goller Bolgesi Cimento Sanayi ve Ticaret AS
IS:GOLTS
|
0.042x |
|
Alquiber Quality SA
MC:ALQ
|
0.715x |
|
YHN Acquisition I Limited Ordinary Shares
NASDAQ:YHNA
|
0.042x |
|
KNH Enterprise Co Ltd
TW:9919
|
-0.038x |
|
S 11 Group Public Company Limited
BK:S11
|
0.020x |
|
Compass Digital Acquisition Corp
NASDAQ:CDAQ
|
0.037x |
|
Scandinavian Astor Group AB
ST:ASTOR
|
0.053x |
|
Dwarikesh Sugar Industries Limited
NSE:DWARKESH
|
0.674x |
Annual Cash Flow Conversion Efficiency for Rallybio Corp (2019–2025)
The table below shows the annual cash flow conversion efficiency of Rallybio Corp from 2019 to 2025. Review Rallybio Corp (RLYB) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $57.96 Million | $-29.81 Million | -0.514x | +35.65% |
| 2024-12-31 | $61.65 Million | $-49.28 Million | -0.799x | -40.84% |
| 2023-12-31 | $106.18 Million | $-60.27 Million | -0.568x | -67.75% |
| 2022-12-31 | $169.32 Million | $-57.28 Million | -0.338x | -30.48% |
| 2021-12-31 | $175.60 Million | $-45.53 Million | -0.259x | -60.01% |
| 2020-12-31 | $136.00 Million | $-22.04 Million | -0.162x | +81.82% |
| 2019-12-31 | $16.86 Million | $-15.03 Million | -0.891x | -- |
About Rallybio Corp
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical … Read more